Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Sold by Principal Financial Group Inc.

VaselineSeptember 1, 2024

0 4 minutes read

Principal Financial Group Inc. reduced its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL – Free Report) by 2.2% in the second quarter, according to the company in its most recent SEC disclosure. The firm owned 1,498,143 shares of the company’s stock after selling 34,329 shares during the quarter. Principal Financial Group Inc. owned 5.43% of Castle Biosciences worth $32,614,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have recently bought and sold shares of the company. RiverPark Advisors LLC boosted its holdings in shares of Castle Biosciences by 362.2% in the first quarter. RiverPark Advisors LLC now owns 2,861 shares of the company’s stock valued at $63,000 after buying an additional 2,242 shares during the last quarter. Assetmark Inc. boosted its holdings in Castle Biosciences by 21.3% in the fourth quarter. Assetmark Inc. now owns 4,736 shares of the company’s stock valued at $102,000 after buying an additional 832 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Castle Biosciences by 70.3% in the first quarter. China Universal Asset Management Co. Ltd. now owns 5,297 shares of the company’s stock valued at $117,000 after acquiring an additional 2,187 shares during the period. WuXi AppTec Co. Ltd. purchased a new stake in shares of Castle Biosciences in the 4th quarter valued at about $143,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Castle Biosciences by 20.5% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,192 shares of the company’s stock worth $177,000 after acquiring an additional 1,395 shares during that period. Institutional investors and hedge funds own 92.60% of the company’s shares.

Castle Biosciences price performance

Shares of NASDAQ:CSTL opened at $29.67 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.02, and a current ratio of 9.25. The company’s fifty day moving average price is $23.25 and its two hundred day moving average price is $22.57. The stock has a market cap of $819.10 million, a PE ratio of -25.80 and a beta of 0.93. Castle Biosciences, Inc. it has a one year low of $12.07 and a one year high of $30.50.

Want more great investment ideas?

Castle Biosciences (NASDAQ:CSTL – Get Your Free Report ) last issued its quarterly earnings data on Monday, August 5th. The company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.47. Castle Biosciences had a negative return on equity of 7.91% and a negative net margin of 12.28%. The company had revenue of $87.00 million for the quarter, compared to analyst estimates of $69.95 million. In the same quarter last year, the company earned ($0.70) earnings per share. On average, analysts estimate that Castle Biosciences, Inc. will post -1.66 EPS for the current fiscal year.

Insiders place their bets

In other news, COO Kristen M. Oelschlager sold 2,793 shares of the company’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $22.06, for a total value of $61,613.58. Following the completion of the transaction, the chief operating officer now owns 145,825 shares of the company’s stock, valued at $3,216,899.50. The transaction was disclosed in a filing with the SEC, which is accessible via this link. In other Castle Biosciences news, Director Daniel Bradbury sold 7,883 shares of the company’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $26.65, for a total value of $210,081.95. Following the sale, the director now directly owns 8,550 shares of the company’s stock, valued at approximately $227,857.50. The sale was disclosed in a filing with the SEC, which can be accessed via this link. Also, COO Kristen M. Oelschlager sold 2,793 shares of Castle Biosciences stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $22.06, for a total value of $61,613.58. Following the completion of the sale, the chief operating officer now owns 145,825 shares of the company’s stock, valued at approximately $3,216,899.50. The disclosure for this sale can be found here. Insiders have sold 36,033 shares of company stock worth $883,633 over the last ninety days. Insiders own 7.20% of the company’s shares.

The Wall Street analyst weighs in

Several equities analysts recently issued reports on the company. Robert W. Baird lifted their price objective on Castle Biosciences from $34.00 to $37.00 and gave the stock an “outperform” rating in a report on Tuesday, August 6th. Stephens restated an “overweight” rating and set a $37.00 target price on shares of Castle Biosciences in a research note on Tuesday, August 6th. Five analysts have rated the stock with a buy rating. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $32.80.

See our latest analysis of Castle Biosciences

Castle Biosciences Profile

(Free report)

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatological cancers, Barrett’s esophagus, uveal melanoma and mental health conditions. Offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a GEP risk stratification test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict the future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic dysplasia, indeterminate dysplasia, or low-grade dysplasia Barrett’s esophagus.